Re: Trails A vs B. They're answer was suggesting the complexity of the task in A was not sufficient enough to allow a statistically significant benefit to be seen, since the patients most afflicted by HD symptoms could still complete it without huge difficulty. Trails B was more complex and, the extra cognition required needed to complete it, taxed those with the greater symptoms allowing a separation in the time to completion.
Re: 12 vs 26 weeks. I recall they said the difference was within the margin of error. They haven't had the time to pour over all aspects of the data so suspect they will (and give individual patient scores) in the upcoming paper.
You are right about the secondary endpoints. This is an exploratory trial, they were taking somewhat of a shotgun approach on some other efficacy measures, just in case it worked in those too and could either power the P3 to demonstrate them as well or discount them. This trial is a search for data, not approval. It's this data that allows them to power P3 for approval.
PBT Price at posting:
93.5¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)